Overview

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

Status:
COMPLETED

Trial end date:
2025-04-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

deucravacitinib
Famotidine